| breast cancer |
upregulation: HBXIP, Bcl-2 |
increased
proliferation, decreased apoptosis |
(93, 94) |
| downregulation:
p21 |
| CRC |
upregulation:
SOX2, GLUT1, miR-1246 |
increased proliferation,
migration, and metastasis;
decreased response to immunotherapy |
(97−99, 119) |
| downregulation: STAT1, IRF1 |
| glioblastoma |
upregulation: SOX2 |
supported the maintenance
of GSCs, dedifferentiation of glioma
cells, radiotherapy resistance |
(101) |
| gastric cancer |
upregulation: Bcl-2, AKT
pathway |
increased proliferation and migration;
decreased
apoptosis |
(60, 103) |
| downregulation: Bax, caspase-3 |
| HCC |
upregulation: Snail |
increased proliferation and metastasis |
(105, 106) |
| downregulation: SOCS2 |
| lung cancer |
upregulation: EGFR, TAZ, BRD4, FRAS1,
ABHD11-AS1 |
increased proliferation and metastasis |
(107−109, 111) |
| osteosarcoma |
upregulation:
LEF1, Wnt/β-catenin pathway |
increased proliferation
and metastasis |
(112) |
| melanoma |
upregulation: MMP2 |
increased migration
and invasion, decreased response
to immunotherapy |
(113, 119) |
| downregulation:
STAT1, IRF1 |
| ovarian cancer |
upregulation: EMT |
increased migration and invasion |
(114) |
| prostate cancer |
upregulation: GLI1 |
increased androgen-independent growth |
(115) |
| bladder cancer |
upregulation: AFF4, CDCP1, MYC, miR221/222, PD-L1 |
increased proliferation
and evasion from immune response |
(116−118) |
| pancreatic
cancer |
modulation of MAPK, ubiquin-related pathways,
and RNA splicing |
increased proliferation,
metastasis, and resistance
to radio- and chemotherapy |
(121, 122) |
| upregulation:
E2F5 |
| AML |
upregulation: c-Myc,
Bcl-2, PTEN |
increased proliferation, decreased apoptosis
and differentiation |
(123−125) |
| CML |
upregulation: PES1 |
increased proliferation |
(108) |
| ESCC |
upregulation: EGR1 |
increased metastasis |
(127) |
